NC
IOVA icon

Nexthera Capital’s Iovance Biotherapeutics IOVA Stock Holding History

Nexthera Capital’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-296,500
Closed -$3.34M – 34
2018
Q3 		$3.34M Buy
+296,500
New +$4.21M 0.64% 32
2016
Q2 		– Sell
-152,266
Closed -$774K – 37
2016
Q1 		$774K Hold
152,266
– – 0.8% 23
2015
Q4 		$1.18M Buy
+152,266
New +$1.06M 1.67% 12

Other funds holding IOVA

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Nexthera Capital's IOVA Position: Q4 2018 in Review

Nexthera Capital sold out of Iovance Biotherapeutics (IOVA) in Q4 2018, closing a stake of 296,500 shares — an estimated $3.34M sold.

Nexthera Capital first reported a position in IOVA in Q4 2015 and held it in 3 quarters. The position peaked at $3.34M in Q3 2018. 139 funds tracked by Wall St. Rank hold IOVA as of Q4 2018.

  • Nexthera Capital reported no remaining Iovance Biotherapeutics position as of Q4 2018 after selling out during the quarter.
  • Nexthera Capital sold 296,500 Iovance Biotherapeutics shares in Q4 2018, an estimated $3.34M.
  • Nexthera Capital first reported a position in Iovance Biotherapeutics in Q4 2015 and held it in 3 quarters.
  • Nexthera Capital's Iovance Biotherapeutics position peaked at $3.34M in Q3 2018.
  • 139 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q4 2018.

Based on Nexthera Capital's 13F filing for Q4 2018, filed 14 Feb 2019.